Mahner S - Search Results

1

Therapeutic Outcome of MR-Guided High-Intensity Focused Ultrasound (MR-HIFU) in Solitary versus Multiple Uterine Fibroids.

Erber B, Schwarze V, Strobl F, Burges A, Mahner S, Goller SS, Rudolph J, Ricke J, Sabel BO. Erber B, et al. Among authors: mahner s. Healthcare (Basel). 2022 Aug 4;10(8):1471. doi: 10.3390/healthcare10081471. Healthcare (Basel). 2022. PMID: 36011128 Free PMC article.

2

Quality of life as a primary endpoint in ovarian cancer trials.

Mahner S, Burges A. Mahner S, et al. Lancet Oncol. 2014 Apr;15(4):363-4. doi: 10.1016/S1470-2045(14)70084-1. Epub 2014 Feb 28. Lancet Oncol. 2014. PMID: 24582485 No abstract available.

3

Coexistence of adenomyosis uteri and endometrial cancer is associated with an improved prognosis compared with endometrial cancer only.

Hertlein L, Rath J, Zeder-Göss C, Fürst S, Bayer D, Trillsch F, Mahner S, Burges A, Jeschke U. Hertlein L, et al. Among authors: mahner s. Oncol Lett. 2017 Sep;14(3):3302-3308. doi: 10.3892/ol.2017.6592. Epub 2017 Jul 18. Oncol Lett. 2017. PMID: 28927080 Free PMC article.

4

No need for NMDA receptor antibody screening in neurologically asymptomatic patients with ovarian teratomas.

Trillsch F, Eichhorn P, Oliveira-Ferrer L, Kuempfel T, Burges A, Mahner S, Havla J. Trillsch F, et al. Among authors: mahner s. J Neurol. 2018 Feb;265(2):431-432. doi: 10.1007/s00415-017-8717-3. Epub 2017 Dec 22. J Neurol. 2018. PMID: 29273845 No abstract available.

5

Peri-operative oral immunonutrition in malnourished ovarian cancer patients assessed by the nutritional risk screening.

Hertlein L, Zeder-Göß C, Fürst S, Bayer D, Trillsch F, Czogalla B, Mahner S, Burges A, Rittler P. Hertlein L, et al. Among authors: mahner s. Arch Gynecol Obstet. 2018 Jun;297(6):1533-1538. doi: 10.1007/s00404-018-4759-8. Epub 2018 Apr 5. Arch Gynecol Obstet. 2018. PMID: 29623417

6

Combined intracavitary and interstitial brachytherapy of cervical cancer using the novel hybrid applicator Venezia: Clinical feasibility and initial results.

Walter F, Maihöfer C, Schüttrumpf L, Well J, Burges A, Ertl-Wagner B, Mahner S, Belka C, Gallwas J, Corradini S. Walter F, et al. Among authors: mahner s. Brachytherapy. 2018 Sep-Oct;17(5):775-781. doi: 10.1016/j.brachy.2018.05.009. Epub 2018 Jun 22. Brachytherapy. 2018. PMID: 29941345 Free article.

7

Interaction of ERα and NRF2 Impacts Survival in Ovarian Cancer Patients.

Czogalla B, Kahaly M, Mayr D, Schmoeckel E, Niesler B, Kolben T, Burges A, Mahner S, Jeschke U, Trillsch F. Czogalla B, et al. Among authors: mahner s. Int J Mol Sci. 2018 Dec 29;20(1):112. doi: 10.3390/ijms20010112. Int J Mol Sci. 2018. PMID: 30597961 Free PMC article.

8

Correlation of the Aryl Hydrocarbon Receptor with FSHR in Ovarian Cancer Patients.

Deuster E, Mayr D, Hester A, Kolben T, Zeder-Göß C, Burges A, Mahner S, Jeschke U, Trillsch F, Czogalla B. Deuster E, et al. Among authors: mahner s. Int J Mol Sci. 2019 Jun 12;20(12):2862. doi: 10.3390/ijms20122862. Int J Mol Sci. 2019. PMID: 31212758 Free PMC article.

9

Extracapsular Lymph Node Involvement in Ovarian Carcinoma.

Heublein S, Schulz H, Marmé F, Angele M, Czogalla B, Burges A, Mahner S, Mayr D, Jeschke U, Schmoeckel E. Heublein S, et al. Among authors: mahner s. Cancers (Basel). 2019 Jul 1;11(7):924. doi: 10.3390/cancers11070924. Cancers (Basel). 2019. PMID: 31266250 Free PMC article.

10

EP3 receptor is a prognostic factor in TA-MUC1-negative ovarian cancer.

Czogalla B, Kuhn C, Heublein S, Schmöckel E, Mayr D, Kolben T, Trillsch F, Burges A, Mahner S, Jeschke U, Hester A. Czogalla B, et al. Among authors: mahner s. J Cancer Res Clin Oncol. 2019 Oct;145(10):2519-2527. doi: 10.1007/s00432-019-03017-8. Epub 2019 Sep 4. J Cancer Res Clin Oncol. 2019. PMID: 31485769

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

470 results

Search Page